Relationship between the prevalence of subclinical tenosynovitis and treatment in patients with RA in clinical remission: STARTER study
Authors' conclusion
The analysis showed a lower prevalence of subclinical inflammatory manifestations detected with ultrasound imaging in those patients treated with the combination therapy than in those in monotherapy.
Study context
- Population
- Consecutive patients with RA in clinical remission, recruited October 2013–June 2014256 completed
- Participants
- 427 patients
- Comparison
- csDMARD + bDMARD combination therapy vs csDMARD or bDMARD monotherapy
- csDMARD + bDMARDn = 56
- csDMARDn = 152reference
- bDMARDn = 48reference
- Primary endpoint
- US-detected joint and/or tendon involvement: Grey-scale (GS) and power Doppler (PD) synovitis and tenosynovitis scores (OMERACT)
- Follow-up
- Baseline, 6 months and 12 months
Methodological detailssub-analysis, consecutive patients, ultrasound (OMERACT scoring)
- Sub-analysis
- Consecutive patients
- Ultrasound (OMERACT scoring)
Primary result
As reported in the abstract
US-detected subclinical inflammation (GS/PD tenosynovitis, PD synovitis)
- csDMARD + bDMARD vs csDMARD: P = 0.025
- csDMARD + bDMARD vs csDMARD: P = 0.047
- csDMARD + bDMARD vs csDMARD: P = 0.01
- csDMARD + bDMARD vs bDMARD: P = 0.02
Original publication
Relationship between the prevalence of subclinical tenosynovitis and treatment in patients with RA in clinical remission: STARTER study. Rheumatology (Oxford). Published 6 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →